tailieunhanh - báo cáo khoa học: "Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report | BioMed Central Journal of Hematology Oncology Open Access Case report Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis A case report Brian J So Tanios Bekaii-Saab Mark A Bloomston and Tushar Patel Address The Ohio State University Medical Center 395 W. 12th Avenue Columbus OH 43210 USA Email Brian J So - Tanios Bekaii-Saab - Mark A Bloomston - Tushar Patel - Corresponding author Published 17 October 2008 Received I October 2008 Journal of Hematology Oncology 2008 1 18 doi 1756-8722-1-18 Accepted 17 October 2008 This article is available from http content 1 1 18 2008 So et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Hepatocellular carcinoma is rare but increasing in prevalence in the United States. Recent studies have shown that sorafenib a multikinase inhibitor can reduce tumor progression in patients with this cancer. However complete remission has not been observed. We report a case of a 78-year old patient with unresectable metastatic hepatocellular carcinoma who had a rapid and complete clinical response following therapy with sorafenib for six months. No evidence of disease recurrence has been noted for 6 months after discontinuation of therapy. Background Hepatocellular carcinoma HCC is the third leading cause of cancer death worldwide with more than 600 000 cases diagnosed every year 1 . Most patients present with advanced and multifocal disease at the time of diagnosis and the median survival in this setting is less than 6 months. Until .